Are there alternative funding sources in sight?

Also grouping together all non-EUR results in multimodal distribution of vars per person, further confounding this analysis. I would def account for that.

Thanks for the response! We see a large excess in both common and rare variants in AFR compared to EUR. It is expected to find proportionally more pathogenic vars in EUR if AFR have proportionally more benign vars bc of generic diversity.

Nice work. I could not understand from the paper how you account for the fact that non-Europeans have more variants per person? E.g. we find that AFR have 2-3x more than EUR, the vast majority of which are benign.